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Summary
The SH2-containing tyrosine phosphatase Shp2 (PTPN11) is required for growth factor and cytokine signaling. Germline
Shp2 mutations cause Noonan Syndrome (NS), which is associated with increased risk of juvenile myelomonocytic leuke-
mia (JMML). Somatic Shp2 mutations occur in sporadic JMML and other leukemias. We found that Shp2 mutants associ-
ated with sporadic leukemias transform murine bone marrow cells, whereas NS mutants are less potent in this assay.
Transformation requires multiple domains within Shp2 and the Shp2 binding protein Gab2, and is associated with hyperac-
tivation of the Erk, Akt, and Stat5 pathways. Mutant Shp2-transduced BM causes a fatal JMML-like disorder or, less
commonly, lymphoproliferation. Shp2 mutants also cause myeloproliferation in Drosophila. Mek or Tor inhibitors potently
inhibit transformation, suggesting new approaches to JMML therapy.S I G N I F I C A N C E
Genetic studies implicate mutations in Shp2 in NS and various forms of leukemia, but the effects of Shp2 mutants on hematopoiesis
have not been evaluated. We show that leukemia-associated Shp2 mutations directly transform primary myeloid progenitors and
cause leukemia in mice, thereby establishing a causal link between Shp2 mutations and oncogenesis. Shp2 mutants also cause
myeloproliferation in flies, indicating that they subvert a highly conserved pathway regulating myeloid cell proliferation/survival and
providing potential genetic approaches to delineating their pathogenic mechanism. Furthermore, we find that NS- and leukemia-
associated mutations have intrinsically different potencies for myeloid transformation, which may have prognostic implications for
NS patients. Finally, analysis of perturbed cytokine signaling mediated by mutant Shp2 suggests new therapeutic approaches to
these disorders.Introduction
Many hematopoietic signaling pathways are controlled by ty-
rosyl phosphorylation, which is regulated by protein-tyrosine
kinases (PTKs) and protein-tyrosine phosphatases (PTPs). Ac-
tivating mutations in PTKs are causally implicated in leukemo-
genesis. For example, the fusion kinase BCR-ABL, expressed
as a consequence of t(9;22), causes chronic myelogenous leu-
kemia (Sawyers, 1999). Similarly, fusions of the PDGFRα,
PDGFRβ, or FGFR1 to oligomerization motifs by chromosomal
translocation contributes to the pathogenesis of other chronic
myeloproliferative disorders (MPD) (Cross and Reiter, 2002;
Pardanani and Tefferi, 2004), whereas activating mutations in
FLT3 occur in >30% of acute myelogenous leukemia (AML)
(Gilliland and Griffin, 2002).
Shp2 (PTPN11) is the first protein-tyrosine phosphatase
(PTP) implicated in leukemogenesis. Germline mutations in
Shp2 cause the autosomal dominant disorder Noonan syn-CANCER CELL : FEBRUARY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIERdrome (NS), characterized by short stature, facial dysmorphia,
and cardiac defects (Tartaglia et al., 2001). A possible associa-
tion between NS and leukemia, particularly juvenile myelo-
monocytic leukemia (JMML), had been noted (Bader-Meunier
et al., 1997; Choong et al., 1999; Side and Shannon, 1997),
suggesting that Shp2 mutations might be leukemogenic. Sub-
sequently, somatic Shp2 mutations were reported in w35% of
sporadic JMML, and at lower incidence in pediatric AML and
myelodysplastic syndrome (MDS) (Loh et al., 2004; Tartaglia et
al., 2003). Shp2 mutations also have been found in w10% of
cases of the most common form of childhood leukemia, B cell
acute lymphoblastic leukemia (B-ALL) (Tartaglia et al., 2004),
and in adult AML (w5%) and a small percentage of solid tu-
mors (Bentires-Alj et al., 2004).
JMML is a rapidly progressive, clonal MPD characterized by
overproduction of tissue-invading myeloid lineage cells (Arico
et al., 1997; Emanuel et al., 1996). JMML bone marrow (BM)INC. DOI 10.1016/j.ccr.2005.01.010 179
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growth factors, and exhibit selective hypersensitivity to granu-
locyte-macrophage colony-stimulating factor (GM-CSF). Ap-
proximately 50% of JMML cases have activating Ras muta-
tions or homozygotic inactivation of the neurofibromatosis type
I gene, NF1, whose gene product, neurofibromin (NF-1), is a
Ras-GTPase activating protein (Ras-GAP) (Cichowski et al.,
2003). Hence, JMML caused by activating Ras or inacti-
vating Nf1 mutation is thought to result from increased Ras
signaling (Arico et al., 1997; Emanuel et al., 1996). Indeed, BM
cells from JMML patients (Bollag et al., 1996) or in murine mod-
els of Nf1 deficiency (Bollag et al., 1996; Largaespada et al.,
1996; Zhang et al., 1998; Le et al., 2004) show increased Ras
activation. Furthermore, the Ras/Erk and PI3K/Akt pathways
are hyperactive in mast cells from Nf1+/− mice (Ingram et al.,
2001), and in immortalized Nf1−/− fetal liver (FL) cells (Donovan
et al., 2002). This ability of hyperactive Ras to transform
hematopoietic cells is highly conserved across evolution, as
Ras mutants cause increased proliferation of Drosophila hemo-
cytes (Asha et al., 2003). Nearly all JMML cases without Ras
or NF1 mutations have Shp2 mutations. As these mutations
usually are mutually exclusive, they may perturb the same my-
eloid cell signaling pathway(s) (Loh et al., 2004; Tartaglia et
al., 2003).
Shp2 is a nonreceptor PTP containing two SH2 domains
(N-SH2, C-SH2), a PTP domain, and a C-tail with tyrosyl phos-
phorylation sites and a proline-rich motif. In RTK and cytokine
signaling, Shp2 is required for full activation of the Ras/Erk
pathway and for multiple receptor-evoked functions, including
cell proliferation, differentiation, and migration (Neel et al.,
2003). In RTK signaling, Shp2 controls recruitment of c-Src ki-
nase (Csk) by dephosphorylating the Csk regulators Pag/Cbp
and paxillin (Ren et al., 2004; Zhang et al., 2004). These data
suggest that Shp2 is required to activate Src family kinases
(SFKs), which then promote Ras activation. Others have ar-
gued that Shp2 regulates recruitment of p120Ras-GAP to
RTKs (Agazie and Hayman, 2003; Klinghoffer and Kazlauskas,
1995) or the tyrosyl phosphorylation and activity of Sprouty
proteins, a family of Ras inhibitors (Hanafusa et al., 2004). Shp2
also regulates other signaling pathways in a cell- and/or recep-
tor-type-specific manner. Some studies indicate that Shp2 is
required for Jak/Stat activation, whereas others suggest an in-
hibitory role (Van Vactor et al., 1998). Shp2 negatively regulates
the PI3K/Akt pathway in EGFR and CSF-1R signaling, but is
required for normal PDGF-and IGF-evoked Akt activation
(Zhang et al., 2002; W. Yang and B.G.N., unpublished data).
All known actions of Shp2 require its PTP activity (Neel et
al., 2003), which is tightly regulated (Barford and Neel, 1998).
In the basal state, the “backside loop” of the N-SH2 domain is
wedged into the PTP domain, preventing catalysis. Binding of
a phosphotyrosyl (pTyr) peptide ligand alters the conformation
of the N-SH2 domain, preventing its interaction with the PTP
domain and activating the enzyme (Barford and Neel, 1998; Hof
et al., 1998). Mutations of key contacts between the N-SH2
and PTP domains yield biochemically “activated” mutants of
Shp2 that enhance growth factor action in vivo (O'Reilly et al.,
1999). Phosphorylation of one or both of its C-terminal tyrosine
residues also is required for Shp2 action in some, but not all,
RTK signaling pathways (Araki et al., 2003).
Most human Shp2 mutations are found in the N-SH2 or PTP
domains, affecting residues that participate in basal inhibition.
Leukemia- and NS-associated mutations often affect the same
residue, but typically, leukemia mutations are less conserva-180tive. For example, D61G and E76D are found in NS, whereas
the two most common leukemia-associated mutants, D61Y
and E76K, are nonconservative substitutions. Immune complex
assays of transiently expressed Shp2 mutants (Tartaglia et al.,
2003) or in vitro studies of recombinant proteins (H.K. and
B.G.N., manuscript in preparation) show that the latter mu-
tations are more enzymatically active than the former.
These data suggest that low levels of Shp2 activation result
in NS, whereas higher levels of activity may be required for
leukemogenesis (Loh et al., 2004; Tartaglia et al., 2003). Con-
sistent with this notion, a knockin mouse model of the NS mu-
tant D61G exhibits the major features of NS, and develops
MPD (Araki et al., 2004). However, in contrast to the pheno-
types of JMML and other Shp2 mutant-associated leukemias
in humans (Arico et al., 1997; Tartaglia et al., 2003, 2004), or
the murine MPDs caused by K-Ras activation (Braun et al.,
2004; Chan et al., 2004) or homozygotic Nf1 deletion (Bollag
et al., 1996; Largaespada et al., 1996; Le et al., 2004), the MPD
in D61G/+ mice is well tolerated, with no progression to fatal
MPD or acute leukemia over w10 months. Yet whether there
are intrinsic differences in the biological properties of different
disease-associated mutants of Shp2 is unclear, and the spe-
cific roles of Shp2 catalytic activity and its other domains in
leukemogenesis remain unknown.
We used retroviral gene transduction to evaluate the biologi-
cal effects, structure/function determinants, and signaling con-
sequences of Shp2 mutants. We found that leukemia-associ-
ated Shp2 mutants are more potent transforming alleles than
NS mutants, cause a fatal systemic MPD resembling JMML
in mice, and thus are potential therapeutic targets for human
malignancies associated with Shp2 mutations. Furthermore,
the ability of Shp2 mutants to transform blood cells is con-
served in Drosophila, providing potential genetic approaches
to analyze Shp2-evoked transformation.
Results
Disease-associated Shp2 mutants cause
myeloid transformation
Disease-associated mutations in Shp2 (Bentires-Alj et al.,
2004; Loh et al., 2004; Tartaglia et al., 2001, 2002, 2003, 2004)
fall into three general classes (Figure 1A). Some occur only in
NS patients (“NS” mutants), others are seen only in patients
with JMML or other neoplasms (“leukemia” mutants), and a
third class is found either in those rare NS patients who de-
velop leukemia or independently as germline mutations in NS
patients and somatic mutations in sporadic neoplasms in un-
related individuals (“NS/leukemia” mutants). NS- and Shp2-
associated neoplasms are uncommon, so it is not clear
whether segregation of specific mutations into apparent patho-
genic classes is coincidental or reflects intrinsic differences in
their biological properties.
To address this issue, we first assessed the effects of the
mutations D61Y and E76K, found only in JMML and other neo-
plasms, on hematopoietic cells. We introduced these mutants
or wild-type (WT) Shp2 into the retroviral expression vector
MSCV-IRES-EGFP (Hawley et al., 1994), and transduced factor-
dependent Ba/F3 cells, but observed no consistent biological
effects of WT Shp2 or either mutant (data not shown). In con-
trast, retroviral-mediated expression of E76K or D61Y, but not
WT Shp2 or the parental retroviral vector in primary murine BMCANCER CELL : FEBRUARY 2005
A R T I C L EFigure 1. Leukemia-associated Shp2 mutants
transform murine BM cells
A: Schematic of disease-associated Shp2 mu-
tants. NS mutants are above the diagram; those
in leukemia and other neoplasms are below.
Some mutations are found in both types of dis-
order.
B: Normal murine BM infected with MSCV-IRES-
GFP-based retroviruses expressing WT Shp2,
E76K, or D61Y or parental control virus (vector)
were plated in duplicate in methylcellulose me-
dia. The number of colonies was counted in the
absence or presence of limiting murine IL-3 (10
pg/ml) or GM-CSF (0.1 ng/ml). Values are the
average of three independent experiments;
bars ± SD.
C: FL cells (E13.5) were infected with retroviruses
expressing Shp2 WT or E76K, and myeloid colo-
nies were quantified as in B. Values represent
the average of two independent experiments;
bars ± SD.
D and E: Myeloid colonies from Shp2 WT-or E76K-
transduced BM cells at various concentrations
of IL-3 (D) or GM-CSF (E).
F: Colony morphology produced by Shp2 WT- or
E76K-transduced BM cells in the presence of
GM-CSF (0.1 ng/ml).(Figure 1B) or FL (Figure 1C), cells consistently evoked cyto-
kine-independent myeloid colonies. Cells transduced with
either mutant also formed more colonies with limiting doses of
either interleukin-3 (IL-3) or GM-CSF (Figures 1B and 1C).
E76K-transduced BM cells showed a leftward shift in dose-
response to either cytokine, although GM-CSF sensitivity was
reproducibly more enhanced (Figures 1D and 1E). Shp2 mu-
tant-expressing myeloid colonies grown in the presence of
cytokines were also larger than normal CFU-GM (Figure 1F).
Normal CFU-GM, as well as the CFU-GM generated by E76K-
transformed BM cells in the presence of cytokines, contained
mature granulocytes and monocyte/macrophage cells. In con-
trast, factor-independent E76K-evoked colonies were primarily
comprised of monocytic cells (data not shown).CANCER CELL : FEBRUARY 2005Differential transforming potency of disease-associated
Shp2 mutants
We next compared the ability of different classes of Shp2 mu-
tants to transform murine BM cells. The leukemia-associated
mutants E76K and D61Y gave rise to larger numbers of cyto-
kine-independent myeloid colonies than the “pure” NS mutants
D61G, N308D, and E76D, whereas NS/leukemia mutants (T73I,
Q506P, E139D) evoked intermediate numbers of colonies (Fig-
ure 2A). Analysis of variance (ANOVA) showed highly significant
differences between all groups (i.e., leukemia versus leukemia/
NS, leukemia versus NS, NS/leukemia versus NS), but no sig-
nificant difference among alleles in the same group (Figure 2A,
legend). Flow cytometric analysis for EGFP expression con-
firmed comparable levels of retroviral transduction (Figure 2B).181
A R T I C L EFigure 2. Differential transforming potency of disease-associated Shp2 mu-
tants
A: Shp2 mutants found exclusively in leukemia or other neoplasms (E76K
and D61Y), in NS and leukemia (T73I, Q506P, and E139D), and in NS alone
(D61G, E76D, and N308D) were transduced into murine BM cells, and
factor-independent myeloid colonies were quantified at day 12. Data re-
present mean colony number ± SD from three independent experiments.
Differences in transforming potency within and between classes of Shp2 mu-
tants were analyzed by two-way ANOVA. Leukemia-associated mutants are
more transforming than NS (p < 0.0001) or NS/leukemia (p < 0.005). NS/leuke-
mia mutants are more transforming than NS mutants (p < 0.01). Individual
mutants within a given group showed no difference in transforming po-
tency.
B: GFP expression in BM cells infected with the mutants in A. Note compa-
rable level of infection with each retrovirus.These data suggest that different classes of Shp2 mutants
have distinct intrinsic myeloid-transforming ability.
Structural requirements for myeloid transformation
by leukemogenic Shp2 mutants
To identify subdomains within leukemogenic Shp2 mutants re-
quired for transformation, we generated second site mutations
in E76K (Figure 3A) and expressed these mutants in murine
BM. Mutating the canonical arginine residue required for pTyr
peptide binding (Pawson and Scott, 1997) in either the
N- (E76K/R32K) or C- (E76K/R138K) SH2 domain of E76K ab-
lated myeloid transforming ability (Figure 3B). Mutation of the
conserved arginine residue within the E76K PTP domain “sig-
nature motif” (Denu et al., 1996) to methionine (E76K/R465M),
which substantially reduces catalysis by Shp2 (data not shown)
and other PTPs (Flint et al., 1997), also eliminated myeloid
transformation (Figure 3B). The R465M mutation was chosen
to avoid the potentially confounding effects (Tonks and Neel,
2001) of “substrate-trapping” mutants (e.g., C459S). Tyrosines
542 and 580 undergo phosphorylation in response to many,182but not all, growth factors, and Shp2 is also tyrosyl phosphory-
lated in response to cytokines such as IL3 and GM-CSF in
factor-dependent cell lines (Bennett et al., 1994; Li et al., 1994;
Welham et al., 1994). Both sites can bind Grb2, and although
Y542 is the major Grb2 binding site in RTK signaling (Araki et
al., 2003; Bennett et al., 1994), both sites are required for opti-
mal Shp2 function in some RTK pathways (Araki et al., 2003).
Both Y542 and Y580 were phosphorylated in IL-3 stimulated
BM cells (Figure 3C), but whereas Y542 mutation (E76K/Y542F)
markedly impaired transformation, Y580 mutation (E76K/
Y580F) had little effect. However, mutation of both tyrosines
(E76K/Y542F/Y580F) eliminated E76K-evoked transformation,
suggesting that Y580 phosphorylation accounts for residual
transformation by E76K/Y542F (Figure 3D). Shp2 also has a
proline-rich domain juxtaposed between the two C-terminal ty-
rosyl residues, and the recent identification of a NS mutation
in this region (Sarkozy et al., 2003) suggests that it might have
an important, if as yet undefined, role. Nevertheless, a proline-
rich domain deletion in E76K (E76K/ 559–568) retained full
transforming ability (Figure 3D). The efficiency of transduction
with each mutant-expressing retrovirus, as assessed by flow
cytometry for EGFP, was comparable to WT Shp2 virus (Figure
3E), and each mutant protein was expressed at comparable
levels in hematopoietic cells (Figure 3F). Thus, the observed
differences in colony formation reflect intrinsic alterations in
transforming properties of the second site mutants.
Gab2 is required for transformation of primary murine
myeloid cells by Shp2 E76K
E76K is fully activated catalytically, even in the absence of pTyr
peptide binding (Tartaglia et al., 2003; H.K. and B.G.N., manu-
script in preparation). The loss of transforming potential follow-
ing mutation of the pTyr binding pocket of either the
N- or C-SH2 domain in E76K implies that proper targeting of
leukemogenic Shp2 mutants to one or more pTyr proteins is
required for transformation. Previous studies identified the
scaffolding adaptor Gab2 (Gu and Neel, 2003; Liu and
Rohrschneider, 2002) as a major Shp2 binding protein in re-
sponse to cytokine stimulation, and Gab2 binding is mediated
by the Shp2 SH2 domains (Gu et al., 1997). Furthermore, Gab2
is essential for myeloid transformation (Sattler et al., 2002) and
leukemogenesis (M.G.M., S. Li, R.A. Van Etten, and B.G.N.,
unpublished data) by BCR/ABL.
We compared the ability of E76K to transform primary my-
eloid cells from BM of WT (Gab2+/+) and Gab2−/− mice. Gab2−/−
mice have normal steady state hematopoiesis (Gu et al., 2001;
Nishida et al., 2002), and their BM cells have normal suscep-
tibility to retroviral infection (Sattler et al., 2002). As expected,
E76K transformed Gab2+/+ BM, resulting in cytokine-indepen-
dent myeloid colonies. However, E76K was unable to transform
BM cells from Gab2−/− mice (Figure 3E). Notably, WT and
Gab2−/− BM cells were comparably susceptible to transforma-
tion by the Tel-Jak2 fusion protein (J. Frantsve, M.G.M., B.G.N.,
and D.G.G., unpublished data). Together with the effects of the
SH2 domain mutants of E76K, these data suggest that E76K
signals essential for myeloid transformation are transmitted by
a Gab2/mutant Shp2 complex.
Leukemogenic Shp2 mutants cause fatal leukemias
To assess the leukemogenic potential of Shp2 mutants, we
transduced WT Shp2, the leukemia-associated Shp2 mutantsCANCER CELL : FEBRUARY 2005
A R T I C L EFigure 3. Structural determinants for myeloid
transformation
A: Schematic of E76K and location of second
site mutants.
B: SH2 and PTP domains are required for myeloid
transformation. The indicated mutants in A were
introduced into MSCV-IRES-GFP, and myeloid
colony formation in the presence or absence of
cytokines was analyzed. A representative ex-
periment from three independent assays yield-
ing comparable results is shown.
C: Shp2 C-terminal tyrosines are phosphorylated
in cytokine-stimulated BM cells. Short-term BM
cultures were factor-depleted for 5 hr, restimu-
lated for 10 min with IL-3 (5 ng/ml), and ana-
lyzed by immunoblotting with phosphospecific
antibodies to Shp2-Y542 or -Y580. Blots were re-
probed with Shp2 antibodies to control for
loading.
D: Role of C-terminal tyrosines and proline-rich
domain in E76K-evoked transformation. Data
represent mean colony number ± SD from two
independent experiments.
E: Comparable GFP expression levels in BM cells
infected with the mutants in B and D.
F: Shp2 mutants are expressed at comparable
levels in hematopoietic cells. Ba/F3 cells were
infected with viral supernatants used for experi-
ments in B and D, sorted for GFP+, and analyzed
by immunoblotting for Shp2.
G: Gab2 is required for myeloid transformation
by E76K. BM cells from Gab2−/− and littermate
WT mice were infected with E76K-expressing ret-
roviruses, and myeloid colony formation was as-
sessed. A representative experiment from two
independent assays that yielded comparable
results is shown.(E76K or D61Y), or parental retrovirus into BM from Balb/c mice
primed with 5-fluorouracil (5-FU), and performed bone marrow
transplants (BMT) into lethally irradiated syngeneic recipients.
Neither parental retrovirus- (data not shown) nor WT Shp2-
infected BM (Figure 4) caused any abnormalities. In contrast,
mice transplanted with E76K- or D61Y-transduced BM devel-
oped leukocytosis within 3 months (Figure 4A), due both to
neutrophilia (Figure 4B) and usually mild, but occasionally
marked, monocytosis (Figure 4C). The leukocytosis was pro-
gressive, with some mice exhibiting white blood cell counts
(WBC) of 40-70,000 per l within six months, although there
was considerable variation in disease progression among indi-
vidual BMT recipients (Figures 4A–4C). Some mice also exhib-
ited lymphocytosis at 3 and/or 6 months. RBC and platelet
counts typically remained within the normal range, but mice
with higher WBC eventually developed anemia and/or throm-
bocytopenia (data not shown). BM recovered from E76K- orCANCER CELL : FEBRUARY 2005D61Y-transplanted mice exhibited increased ability to generate
cytokine-independent colonies, and, like directly transduced
BM cells, IL-3 or GM-CSF hypersensitivity (Figure 4D). Begin-
ning at 6–7 months, a significant percentage of D61Y- or E76K-
transplanted mice (w50%) appeared moribund (requiring sac-
rifice) or were found dead. Transplanted mice continued to die
over the succeeding 12–18 months, with >90% eventually suc-
cumbing. There were no deaths among recipients of WT Shp2-
or parental retrovirus-transduced BM during this time (Figure 4E).
Histology revealed two types of neoplastic pathology caused
by D61Y and E76K. Most mice (w60%) had severe MPD (Fig-
ure 5A). Blood smears showed substantially increased neutro-
phils, a smaller proportionate increase in monocytes, and in
some cases, occasional (<10%) blasts (Figure 5A, top left
panel and data not shown). The BM showed a marked myeloid
hyperplasia, predominantly consisting of granulocytic forms at
various stages of differentiation (Figure 5A, upper middle panel).183
A R T I C L EFigure 4. Shp2-transduced BM causes fatal
hematopoietic disease upon BMT
A–C: WBC (A), neutrophil (B), and monocyte (C)
counts from mice transplanted with BM trans-
duced with the indicated retroviruses and ana-
lyzed at 3 or 6 months.
D: Increased factor-independent colony forma-
tion in BM from transplanted mice. BM was reco-
vered from the indicated transplanted mice at
4–5 months, and myeloid colony assays per-
formed. Shown is a representative experiment
from four independent assays with similar results.
E: Kaplan-Meier curves of mice transplanted
with D61Y- (n = 10) or E76K- (n = 15) transduced
BM. Survival of Shp2 mutant-transduced recipi-
ents was substantially diminished compared to
Shp2 WT (n = 15) (p < 0.0001). Although there
was a trend toward decreased survival of E76K
compared with D61Y, this did not reach statisti-
cal significance (p < 0.255).There was marked splenomegaly with extensive infiltration of
maturing myeloid cells similar to that seen in the BM (Figure
5A, lower panels), as well as perivascular infiltration of neutro-
phils in the liver (Figure 5A, right upper panel). This fatal, tissue-
infiltrating MPD contrasted with the chronic MPD found in
Shp2 D61G/+ mice (Araki et al., 2004). Most remaining mice
developed lymphoblastic leukemia/lymphoma (w20%) or a
mixture of lymphoblastic leukemia/lymphoma and MPD
(w20%). Mice with lymphoproliferative disease had enlarged
lymph nodes and thymuses (data not shown), with lympho-
blasts in their peripheral blood (Figure 5B, top left panel) that
also infiltrated the BM (Figure 5B, upper middle panel), splenic
white pulp (Figure 5B, lower panels), and liver (Figure 5B, upper
right panel).
Flow cytometry of BM and spleen cells showed marked ex-
pansion of donor-derived cells, as indicated by EGFP expres-
sion, in E76K- and D61Y-transplanted mice (Figures 6A and
6C). Thus, E76K or D61Y-transduced BM cells had a survival184and/or proliferation advantage in vivo, as in ex vivo colony as-
says (Figures 1 and 2). Mice with histological MPD (as defined
in Figure 5A) had increased numbers of immature myelomono-
cytic cells (Mac-1hi/Gr-1lo) in BM and spleen (Figures 6B and
6C). BM progenitor analysis showed expansion of the IL-7Rα-
Lin-Sca-1-c-Kit+CD34+FcγR+ population that corresponds to
the CMP/GMP (common myeloid progenitor/granulocyte mac-
rophage progenitor) populations (Akashi et al., 2000). In con-
trast, mice with pure lymphoproliferative disease had no
increase in myeloid cells (Figure 6D). Instead, CD4−/CD8+ cells
(and in one case, CD4+/CD8+ cells; data not shown) were in-
creased markedly in BM, spleen, and lymph nodes of these
mice (Figure 6D). The CD4−/CD8+ cells were immature T lym-
phoid precursors with downregulated CD4 expression, as they
expressed terminal deoxyribonucleotidyl transferase (TdT) uni-
formly (Figure 5B; lower right panel). Therefore, the Shp2-
evoked lymphoproliferative disease is best characterized as T
acute lymphoblastic leukemia (T-ALL)/lymphoma.CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 5. Shp2 mutants cause leukemia in mice
and flies
A: Shp2-evoked MPD. Top row, left panel: Blood
smear (1,000×) from mouse with Shp2-evoked
MPD showing marked neutrophilia. Top row,
middle panel: BM section (400×) showing promi-
nent hypercellularity with mature myeloid (gran-
ulocytic) predominance. Top row, right panel:
Liver section (200×) showing periportal vascular
invasion of myeloid cells. Bottom row, left panel:
massive splenomegaly in E76K-transplanted
mice. Bottom row, middle and right panels:
Spleen section at 200× (middle) and 400× (right)
showing infiltration of spleen with myeloid ele-
ments.
B: Shp2 mutants also cause lymphoproliferation.
Top row, left panel: Blood smear (1,000×) show-
ing increased lymphocytes and occasional
lymphoblasts. Top row, middle panel: BM sec-
tion (1,000×) showing hypercellularity with large
number of lymphoblasts. Top row, right panel:
Liver section (100×) showing periportal invasion
with immature lymphoid cells. Bottom row:
Spleen section at 40× (left) and 400× (middle)
showing massive expansion of white pulp with
large numbers of blasts. Right panel shows
spleen section (400×) demonstrating efface-
ment of architecture with abnormal lymphoid
elements and TdT immunoreactivity.
C: E76K causes MPD in D. melanogaster. A strain
expressing Shp2 E76K under the control of the
GAL4 UAS (UAS-E76K/+) was crossed to a driver
strain (GcGAL4) that expresses GAL4 in larval,
and plasmatocyte concentrations (mean ± SEM)
were determined. Right panel: E76K-evoked
plasmatocytes have normal morphology but
vary in size. CgGAL4/ UAS-E76K larvae were
bled into a drop of halocarbon oil, and exam-
ined under a phase contrast microscope. The
size variation suggests expansion of a more im-
mature population.Following adoptive transfer to sublethally irradiated recipi-
ents, spleen cells from mice with E76K- or D61Y-evoked MPD
(n = 4 each) did not transfer disease over a nine-month period.
In contrast, T-ALL/lymphoma was readily transplantable, with
all recipients (n = 8) dying of a similar disease within one
month. Southern blot analysis of proviral integration sites from
mice with E76K- or D61Y-evoked MPD or T lymphoid leukemia
indicated that both disorders were oligoclonal, with 3–7 integ-
ration sites per sample (data not shown). Oligoclonality, and
the significant lag before the appearance of frank disease, sug-
gests that additional events may collaborate with Shp2 muta-
tions to cause MPD/leukemia.CANCER CELL : FEBRUARY 2005Leukemogenic Shp2 mutations cause MPD in Drosophila
Activating Ras mutations cause a model MPD in D. melanogas-
ter (Asha et al., 2003), and flies express a highly conserved
Shp2 ortholog (Freeman et al., 1992; Perkins et al., 1992).
Therefore, we assessed the effects of E76K expression in he-
mocytes using the GAL4 system (Brand and Perrimon, 1993).
UAS-E76K stable transgenic strains, in which E76K expression
is controlled by yeast GAL4 activation sequences, were mated
to a CgGAL4 transgenic strain (Asha et al., 2003), which
strongly expresses the GAL4 transcription factor in larval plas-
matocytes and fat body tissues. The UAS-E76K strain or the
CgGAL4 strain alone, crossed to WT Oregon R flies, served as185
A R T I C L EFigure 6. Flow cytometric analysis of Shp2-
evoked leukemias
A–C: Shp2-evoked MPD. A: Marked expansion
of GFP+ (virally infected donor cell) population
in E76K- and D61Y-transplanted recipients. B: Ex-
panded population of immature myeloid cells
in recipients of E76K- and D61Y-transduced BM.
C: Myeloid progenitor analysis of BM of trans-
planted mice. Note expansion of IL-7Rα-Lin-Sca-
1-c-Kit+CD34+FcγR+ population corresponding
to CMP/GMP in E76K-evoked MPD (middle
panel). Expanded GFP+ and Mac1+ population
also is evident, whereas B220+ cells are unaf-
fected.
D: Subset of recipients develop T-ALL/lym-
phoma. Cells from the indicated tissues were
analyzed for T cell (CD4, CD8) and myeloid
(Mac-1, Gr-1) markers. Note expansion of a
CD4−/CD8+ population in all tissues.controls. E76K expression caused an w6-fold increase in the
number of plasmatocytes, which are myeloid-like cells that
comprise w95% of circulating hemocytes in normal larvae
(Dearolf, 1998; Meister, 2004). Mutant plasmatocytes had nor-
mal morphology but varied in size, suggesting that many of
the cells are immature (Figure 5C). Overall, the effects of E76K
overexpression were qualitatively similar to the effects of acti-
vated Ras or Raf mutants. However, in previous experiments
using the same driver strain, Ras or Raf gain-of-function mu-
tants caused accumulation of circulating larval blood cells to
w200 × 106 cells/ml (Asha et al., 2003). Neither E76K nor acti-
vated Ras increased the numbers of differentiated lamello-
cytes, another form of larval blood cell, in contrast to the ef-
fects of dominant forms of the Janus kinase (Jak) ortholog
Hopscotch (Harrison et al., 1995; Luo et al., 1995).
Leukemia-associated mutants of Shp2 activate multiple
signaling pathways
The Ras/Erk and PI3K/Akt pathways are hyperactive in immor-
talized Nf1−/− FL cells (Donovan et al., 2002) and Nf1+/− mast
cells (Ingram et al., 2001). To assess the effects of leukemo-186genic Shp2 on cytokine signaling, BM from mice transduced
with WT Shp2, D61Y, or E76K was cultured in IL-3. Under these
conditions, BM normally gives rise to mast cells (BMMC),
whose proliferation slows by 5–6 weeks and eventually ceases.
In contrast, D61Y- or E76K-BMMC remained highly prolifera-
tive at 6 weeks (Figure 7A), although still dependent on IL-3
for survival and proliferation. Such cultures also immortalized
spontaneously (without crisis) to generate IL-3 dependent lines
with mast cell characteristics, as demonstrated by uniform
staining with toluidine blue and strong degranulation responses
to IgE receptor stimulation (data not shown).
We compared the response to IL-3 stimulation of BMMC (at
6 weeks, before immortalization) expressing WT Shp2 and
leukemogenic mutants. Marked differences were observed in
tyrosyl phosphoproteins from basal (factor-starved) and IL-3-
stimulated WT and mutant-expressing BMMC. Several pro-
teins exhibited reproducibly decreased tyrosyl phosphoryla-
tion, suggesting that they might be substrates of the activated
mutants (Figure 7B, open arrowheads). Others showed in-
creased tyrosyl phosphorylation (Figure 7B, closed arrow-
heads), consistent with activation of one or more PTKs by leu-CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 7. Effects of leukemogenic Shp2 mutations on BMMC
A: Proliferation of BMMC (six weeks) derived from recipients of BM trans-
duced with WT Shp2 or the indicated mutants in response to IL-3 (5 ng/ml).
B–D: BMMC were starved, stimulated with IL-3 (1 ng/ml) for the indicated
times, and total cellular phosphotyrosine, and Erk, Akt, and Stat-5 activity
was assessed by immunoblotting. Specific decreases (open arrowheads)
in several phosphotyrosyl proteins, some of which may be direct substrates,
and increased tyrosyl phosphorylation of others (closed arrowheads) are
seen in cells expressing E76K (B). Note increased basal and stimulated ac-
tivity of Erk and Akt (C), and increased Stat5 activation (D) caused by
leukemogenic Shp2 mutants.
E: Effects of the Mek inhibitor U0126 (U0) and/or the Tor inhibitor rapamycin
(Rapa) on E76K-evoked myeloid colony formation.
F: Effects of U0126 and/or rapamycin on colony formation by WT BM cells
in the presence of IL-3 (5 ng/ml).kemogenic mutants. Compared to WT BMMC, basal Erk and
Akt activity, as monitored by phosphospecific antibody immu-
noblotting, was increased in BMMC-expressing leukemogenic
Shp2 mutants, and their activation in response to IL-3 stimula-
tion was sustained (Figure 7C). Stat5 activation also was in-
creased and sustained in leukemogenic mutant-transformed
BMMC, consistent with increased activity of at least one PTK
in these cells (Figure 7D). Thus, leukemia-associated Shp2 mu-
tants activate multiple downstream signaling pathways known
to be important for transformation.
Current treatments for hematopoietic diseases caused by
Shp2 mutations are often ineffective. Given the effects of leu-
kemogenic mutants on cytokine signaling (Figures 7B–7D), we
tested the effects of inhibiting Erk activation by using the MekCANCER CELL : FEBRUARY 2005inhibitor UO126, the mTOR arm of the PI3K/Akt pathway, using
the mTOR inhibitor rapamycin, or both pathways on E76K-
evoked myeloid transformation (Figure 7E). Mek inhibition
alone (at 20 M) caused w85% inhibition of colony formation.
Rapamycin at the lower end of the therapeutic range for immu-
nosuppression (5 nM) also inhibited transformation. Coadmin-
istration of these two drugs resulted in superadditive inhibition.
The doses used resulted in inhibition of their target signaling
pathways (p-Erk, p-S6) in E76K-expressing cells (data not
shown). Furthermore, consistent with previous studies (Mohi et
al., 2004), these drugs alone or in combination have little effect
on normal BM cells (Figure 7F). Because our structure-function
analyses showed that Shp2 catalytic activity was required for
transformation by leukemogenic Shp2 mutants, we also tested
the nonspecific PTP inhibitor sodium orthovanadate. At con-
centrations corresponding to ~one-tenth the serum vanadium
levels achieved in a clinical trial of sodium metavanadate as an
anti-diabetogenic agent (Goldfine et al., 1995), sodium ortho-
vanadate completely prevented myeloid colony formation by
E76K. However, this effect was not specific for Shp2 mutant-
transformed cells, as normal myeloid colony formation was
also inhibited at these doses (data not shown).
Discussion
We addressed several questions about the Shp2 mutations
found in NS and in some types of myeloid and lymphoid leuke-
mias: (1) what are the effects of leukemia-associated Shp2 mu-
tations on primary hematopoietic cells ex vivo and in vivo; (2)
do NS- and leukemia-associated mutants have intrinsic differ-
ences in bioactivity; (3) what domains within the Shp2 molecule
contribute to leukemogenesis by Shp2 mutants; and (4) how
do leukemogenic mutants perturb hematopoietic cell signal-
ing? We find that leukemia-associated mutant(s) transform my-
eloid progenitors to factor independence and increase their cy-
tokine sensitivity. Transformation requires Shp2 catalytic
activity, intact C-terminal tyrosines, and the ability of both SH2
domains to bind pTyr peptides. The latter probably reflects a
need for mutant Shp2 proteins to bind Gab2, which is itself
required for myeloid transformation by some PTK-fusion onco-
genes (Sattler et al., 2002). Leukemia-associated Shp2 mutant-
transformed BM causes a fatal, tissue-infiltrating MPD that re-
sembles human JMML and the MPD evoked by activated Ras
or Nf1 deficiency, and/or T-ALL/lymphoma. Leukemia-associ-
ated mutants aberrantly activate multiple hematopoietic signal-
ing cascades, including the Ras/Erk, PI3K/Akt, and Stat5 path-
ways, and blocking two of these pathways abrogates myeloid
transformation ex vivo. Our results thereby establish a causal
role for Shp2 mutations in leukemogenesis and suggest new
therapeutic approaches to these disorders.
Shp2 mutants evoke cytokine independence and increase
cytokine-evoked colony size (Figure 1). Moreover, like the
factor-independent colonies from human JMML BM (Emanuel
et al., 1996), Shp2 mutant colonies (in the absence of cyto-
kines) are predominantly monocytic (data not shown). Thus,
leukemogenic Shp2 mutants promote myeloid cell survival
(factor-independence) and proliferation (colony size), and pref-
erentially enhance monocytoid differentiation. In contrast to a
previous study (Loh et al., 2004), we failed to observe effects
of D61Y or E76K on factor-dependent cell lines (e.g., Ba/F3).
Instead, our data suggest that Shp2 mutants exhibit cell type-187
A R T I C L Eselective transforming ability, reminiscent of the tissue-specific
effects of the NS mutation D61G, in knockin mice. Although the
molecular basis for cell selectivity remains unknown, biological
efficacy of the D61G allele in mice correlates with its ability to
promote Erk hyperactivation in specific tissues (Araki et al.,
2004). Notably, Erk activity is unaffected in Ba/F3 cells ex-
pressing leukemogenic Shp2 mutants (Loh et al., 2004; M.G.M.
and B.G.N., unpublished data), but increased in mutant Shp2-
expressing BMMC (Figure 7C).
Ras, NF1, and Shp2 mutations are almost always mutually
exclusive in leukemia (Loh et al., 2004; Tartaglia et al., 2003),
suggesting that they affect a common pathway. Yet although
the effects of leukemogenic Shp2 mutants are similar to those
of Ras and Nf1 mutations, there are potentially important differ-
ences in murine models. NF1 deficiency reportedly results in
selective GM-CSF hypersensitivity (Bollag et al., 1996; Lar-
gaespada et al., 1996; Le et al., 2004), although others ob-
served more pleiotropic effects on cytokine/growth factor re-
sponsiveness (Zhang et al., 1998). In contrast, leukemogenic
Shp2 mutants (Figure 1) and activated K-Ras (Braun et al.,
2004) cause increased sensitivity to both IL-3 and GM-CSF.
Human and murine myeloid progenitors may have some funda-
mental differences in their response to Shp2, Ras, and NF1
mutations, as studies of large numbers of JMML cases (which
likely included examples of each type of mutation) showed se-
lective GM-CSF hypersensitivity in all (Arico et al., 1997; Eman-
uel et al., 1996). However, the murine MPD caused by Nf1 defi-
ciency (Le et al., 2004) appears less severe than that caused
by activated K-Ras (Braun et al., 2004), raising the possibility
that JMML caused by activating Ras (and possibly, Shp2) mu-
tations may be more aggressive than MPD associated with
NF1 deficiency.
Approximately 25% of NS patients develop evidence of mild
MPD (Bader-Meunier et al., 1997; Choong et al., 1999; Side
and Shannon, 1997), the overwhelming majority of which re-
solve. Nevertheless, for unclear reasons, a very small number
of such patients develop JMML and/or other Shp2 mutant-
associated leukemias. Our data show that Shp2 mutations
have intrinsic differences in leukmogenicity (Figure 2). Using
transformation to factor independence as an assay, it may be
possible to prospectively classify the relative leukemogenic risk
of a given Shp2 mutation in NS patients and potentially in-
tervene before overt leukemia develops.
Transplantation of E76K- or D61Y-transduced BM results in
an oligoclonal MPD (Figure 4E). Oligoclonality and the fairly
long latency of this disorder suggest that additional events be-
sides Shp2 mutation may be required to cause tissue-invasive
MPD. There also is a lag before MPD develops in mice with
induced expression of mutant K-Ras (Braun et al., 2004; Chan
et al., 2004) or Nf1 deletion (Le et al., 2004). One attractive
possibility is that a second event results in autocrine pro-
duction of a cytokine that signals through the IL-3 receptor;
indeed, transformed Nf1−/− FL cells produce GM-CSF (Dono-
van et al., 2002). Alternatively, latency and oligoclonality could
also be explained if the target cell for Shp2-evoked MPD is
rare. Although a differentiated progenitor population (CMP/
GMP) is expanded in Shp2 mutant-evoked MPD (Figure 6C),
identification of the cell type transformed by Shp2 will require
prospective purification and infection of HSC and/or progeni-
tors with leukemogenic Shp2 mutants.
The leukemia-associated mutant E76K (and D61Y; data not188shown), like activated Ras (Asha et al., 2003), evokes MPD in
Drosophila (Figure 5C). These data indicate that Ras and Shp2
mutants engage a highly conserved signaling mechanism(s) to
transform hematopoietic cells. But whereas the effects of Shp2
and Ras mutants on fly hemocytes are qualitatively similar, Ras
evoke more (20- to 50-fold) hemocyte proliferation. Although
we cannot exclude the possibility that E76K functions less ef-
fectively in fly hemocytes than in mammalian myeloid progeni-
tors, these findings may provide further evidence of important
differences in leukemogenesis by Ras and Shp2 mutations.
Hyperactivation of the Jak-Stat pathway also leads to hemato-
poietic abnormalities in flies (Harrison et al., 1995; Luo et al.,
1995). However, hyperactive Hop Jak kinase activity enhances
the encapsulation response of blood cells, leading to a large
increase in lamellocytes. The lack of a lamellocyte response in
E76K-expressing flies suggests that E76K does not act by
globally increasing Jak signaling.
Some mice transduced with Shp2 mutants develop T-ALL/
lymphoma. A recent study did not identify Shp2 mutations in
small numbers of human T-ALL patients (Tartaglia et al., 2004),
but a larger survey may be warranted. We also failed to ob-
serve the other hematopoietic disorders (AML, B-ALL) associ-
ated with human Shp2 mutations. Most likely, as suggested
previously (Gilliland and Tallman, 2002), Shp2 mutants must
cooperate with other mutations to cause B-ALL or AML. Trans-
locations involving the homeobox gene MLL are common in
AML associated with Shp2 mutations (Tartaglia et al., 2004), so
it will be interesting to see the effects of leukemia-associated
Shp2 mutants in murine models of abnormal MLL function
(Armstrong et al., 2003).
Our results provide insight into how leukemogenic Shp2 mu-
tants transform myeloid cells. SH2 domain function is required
(Figure 3B), most likely to direct binding to Gab2 (Figure 3G).
Gab2 also is required for myeloid transformation by BCR/ABL
(Sattler et al., 2002), and resides within a fairly common ampli-
con in AML (Zatkova et al., 2004), suggesting a potential role
for Gab/Shp2 signaling in AML pathogenesesis. Because PTP
activity also is essential (Figure 3B), leukemogenic Shp2 pre-
sumably must dephosphorylate one or more key targets to ef-
fect transformation. Candidates include proposed substrates
of normal Shp2 (see Introduction) and/or the multiple hypo-
phosphorylated pTyr-proteins in BMMC expressing leukemia-
associated mutants (Figure 7B). Y542 also is required for opti-
mal transformation by leukemogenic Shp2, whereas Y580 has
a minor role (Figure 3D). Although both Y542 and Y580 bind
Grb2, and have been suggested to promote Ras activation via
recruitment of the guanine nucleotide exchange protein Sos
(Bennett et al., 1994; Li et al., 1994), Y580 can enhance Shp2
action without any effect on Grb2 binding (Araki et al., 2003).
Another suggested function for Shp2 tyrosine phosphorylation
is stimulation of Shp2 catalytic activity (Lu et al., 2001). How-
ever, E76K is fully activated in the absence of any pTyr peptide,
so this model cannot explain the requirement for the C-terminal
tyrosines in Shp2-evoked transformation. If the proline-rich do-
main has a function in transformation, it most likely is inhibitory,
as E76KPro had unperturbed transforming ability (Figure 3D).
Similar to the effects of Nf1 deficiency (Donovan et al., 2002;
Ingram et al., 2001; Le et al., 2004), leukemogenic Shp2 in-
creases BMMC proliferation (Figure 7A) and enhances Erk and
Akt activation (Figure 7C). The latter probably reflects in-
creased Ras activation, as Ras activates Erk via the Ras/Raf/CANCER CELL : FEBRUARY 2005
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and binds and stimulates the PI3K p110 catalytic subunit
(Khwaja et al., 1997). Shp2 mutant-expressing BMMC also
have increased Stat5 phosphorylation (Figure 7D), most likely
due to increased Jak2 or SFK activity. We favor the latter, given
our finding that Shp2 promotes SFK activation in RTK signaling
(Zhang et al., 2004) and the effects of Shp2 mutants in Dro-
sophila (see above). Indeed, preliminary data show an in-
creased phosphorylation of Src Tyr416 in E76K-expressing
BMMC (M.G.M. and B.G.N., unpublished data).
These signaling abnormalities suggest new therapeutic ap-
proaches. Mek inhibitors, as well as inhibitors of the upstream
kinase Raf, are in clinical trials (Sebolt-Leopold, 2000; Wilhelm
et al., 2004); our data (Figure 7E) suggest that they may be
efficacious against mutant Shp2-transformed cells. Rapamycin
inhibits one arm of the Akt pathway, and is FDA-approved for
immunosuppresion (Bjornsti and Houghton, 2004). Rapamycin
doses well within the typical therapeutic serum levels achieved
in patients (MacDonald et al., 2000) also inhibited Shp2-evoked
myeloid transformation, and combining Mek and Tor inhibition
was even more potent (Figure 7E). Given the often fatal out-
come of JMML and other Shp2-associated neoplasms, clinical
trials of Mek and/or Tor inhibitors should be considered, at
least until selective Shp2 inhibitors are developed. Our murine
model of Shp2-evoked MPD may provide a useful system to
test these and other potential therapeutic approaches.
Experimental procedures
Retroviral transduction and BM colony-forming assays
High-titer retroviral stocks of WT or mutant Shp2 were prepared by transient
transfection of 293T cells (Million and Van Etten, 2000). BM transduction
and colony assays were performed using MethoCult M3234 medium (Stem
Cell Technologies, Vancouver) in the presence or absence of cytokines, as
described (Sattler et al., 2002). In some experiments, E13.5 FL cells were
transduced with Shp2-expressing retroviruses and assayed for colony for-
mation.
BMT, histopathology and immunocytochemistry
BM cells (106) from 5-fluorouracil (5FU)-primed Balb/c mice transduced with
Shp2 WT- or E76K- or D61Y-expressing retroviruses were injected into tail
veins of lethally irradiated (2 × 450 cGy) female recipients, as described
(Schwaller et al., 1998). The method of Kaplan and Meier was used to gener-
ate survival curves, and significance was evaluated by log rank test.
Murine organs were collected and fixed in 10% neutral buffered formalin
for at least 72 hr and embedded in paraffin. Tissue sections (4 m) were depar-
affinized in xylene, rehydrated, and stained with hematoxylin and eosin (H&E).
For TdT immunostaining, slides were pretreated with Peroxidase Block
(DAKO, Carpinteria, CA) for 5 min, followed by blocking of nonspecific bind-
ing sites with goat serum, incubation with anti-TdT antibodies (DAKO, Car-
pinteria, CA), and detection with anti-rabbit horseradish peroxidase-conju-
gated antibodies (Envision plus, DAKO). Immunoperoxidase stains were
developed using a DAB chromogen (DAKO), and counterstained with Har-
ris hematoxylin.
Flow cytometry
Single cell suspensions from BM, spleen, and LN were prepared as de-
scribed previously (Schwaller et al., 1998), and washed in PBS containing
0.1% NaN3 and 0.1% BSA. Fc receptor-mediated binding was blocked by
preincubation with 2.4G2 hybridoma supernatants (anti-CD16/CD32; ATCC,
Rockville, MD). Aliquots (0.5–1.0 × 106 cells) were stained with monoclonal
antibodies specific for Mac-1 (CD11b), Gr-1, CD4, CD8α, Thy1.2, or B220
(CD45R), and conjugated to fluorescein isothiocyanate (FITC), phycoer-
ythrin (PE), or biotin. All antibodies were from Pharmingen (San Diego, CA).
Flow cytometry was performed with a FACSCalibur (Becton-Dickinson,
Mountain View, CA) and analyzed with CELLQUEST software. HSC/progen-CANCER CELL : FEBRUARY 2005itor analysis was performed as described (Akashi et al., 2000) to quantify
IL-7Rα-Lin-Sca-1-c-Kit+CD34+FcγRII/IIIlo common myeloid progenitors
(CMP), IL-7Rα-Lin-Sca-1-c-Kit+CD34+FcγRII/IIIhi granulocyte-monocyte pro-
genitors (GMP), and IL-7Rα-Lin-Sca-1-c-Kit+CD34-FcγRII/IIIlo megakaryo-
cyte-erythrocyte progenitors (MEP).
Generation of transgenic flies
E76K cDNA, cloned into the Drosophila P element transformation vector
pUAST, was injected (Duke University Model System Genomics Facility),
and two independent transgenic strains (identified by eye color) were reco-
vered. Both were homozygous viable and fertile, and behaved comparably.
Flies were maintained at 18°C on standard cornmeal/agar/molasses/yeast/
Tegosept medium. Crosses were carried out at 25°C. Circulating plasmato-
cyte concentrations were measured as described (Zinyk et al., 1993).
BMMC and short-term BM assays
BMMC were generated as described previously (Gu et al., 2001). After w5
weeks, a homogeneous population of nonadherent cells was apparent. Cell
aliquots were stained with Wright-Giemsa and toluidene blue to confirm
their mast cell phenotype, and used for assays. For proliferation assays,
5 × 106 cells were seeded into 10 cm dishes and viable cells were quantified
over 5 days. For biochemical analyses, BMMC were deprived of serum and
growth factors for 5 hr, stimulated with mIL-3 (1 ng/ml) for the indicated
times, washed 2× with PBS, and lysed in boiling SDS-PAGE sample buffer.
Immunoblotting was performed using phosphospecific antibodies against
p44/42 Erk, Akt Ser 473, or Stat5-Tyr 694 (Cell Signaling Technology, Bev-
erly, MA). Detection was by enhanced chemiluminescence (ECL). To control
for equal loading, blots were reprobed with antibodies against total Erk2
(Santa Cruz Biotechnology).
WT BM cells were cultured for 10 days in IL-3-containing IMDM medium,
factor-depleted for 5 hr, and restimulated for 10 min with IL-3 (5 ng/ml). Cell
lysates were resolved by SDS-PAGE and immunoblotted with phosphos-
pecific antibodies to Shp2-Tyr542 or -Tyr580 (Cell Signaling Technology, Bev-
erly, MA).
Statistical analysis
Paired data were evaluated by Student’s t test. Simultaneous comparisons
between multiple groups were performed using two-way ANOVA, using
commercially available software (GraphPad Software Inc., San Diego, CA).
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